<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02666742</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00003241</org_study_id>
    <secondary_id>CV185-415</secondary_id>
    <nct_id>NCT02666742</nct_id>
  </id_info>
  <brief_title>DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation</brief_title>
  <acronym>STROKE-VT</acronym>
  <official_title>SafeTy and Efficacy of Direct Oral Anticoagulant Versus Aspirin for Reduction Of RisK of CErebrovascular Events in Patients Undergoing Ventricular Tachycardia Ablation (STROKE-VT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kansas City Heart Rhythm Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kansas City Heart Rhythm Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kansas City Heart Rhythm Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn if taking a drug called direct oral anticoagulant after&#xD;
      an ablation procedure keeps blood clots from forming and lowers the chance of having a stroke&#xD;
      in patients with ventricular tachycardia or arrhythmia (VT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ventricular tachycardia (VT) or fast heart rhythm is a condition where the lower chambers&#xD;
      (ventricles) of the heart beat too fast. This condition can be life threatening because these&#xD;
      ventricles are the main pumping chambers of the heart. The fast heartbeat is caused by&#xD;
      electrical impulses that travel incorrectly in your heart.&#xD;
&#xD;
      One way to treat VT is to have a catheter ablation procedure. A catheter ablation is a&#xD;
      procedure that creates scar tissue in the heart to interrupt the electrical impulses that&#xD;
      create irregular heart rhythms.&#xD;
&#xD;
      It is possible that the ablation procedure might cause a blood clot to form. The blood clot&#xD;
      can stop blood flow to the brain and cause a stroke. When blood flow is interrupted to a&#xD;
      certain part of the brain, that part does not receive enough oxygen. As a result of the&#xD;
      stroke the affected areas of the brain are unable to function normally.&#xD;
&#xD;
      Direct oral anticoagulant (DOAC) is a blood thinning drug, also called an anticoagulant. It&#xD;
      interferes with the body's natural blood clotting ability by inactivating a specific enzyme&#xD;
      that the body needs to form blood clots.&#xD;
&#xD;
      Participation in this study will last about 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 16, 2017</start_date>
  <completion_date type="Actual">April 30, 2021</completion_date>
  <primary_completion_date type="Actual">May 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Transient Ischemic Attack</measure>
    <time_frame>First 30 days of post ablation</time_frame>
    <description>Transient ischemic attack(TIA) - defined as a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Stroke</measure>
    <time_frame>First 30 days of post ablation</time_frame>
    <description>Stroke - incidence of ischemic stroke - defined as an episode of neurological dysfunction caused by focal cerebral, spinal, or retinal infarction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Asymptomatic Cerebral Event on MRI - 24 Hours</measure>
    <time_frame>24 Hours post ablation</time_frame>
    <description>MRI detected asymptomatic cerebrovascular events (ACE) at 24 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Asymptomatic Cerebral Event on MRI - 30 Days</measure>
    <time_frame>24 Hours to 30 days of post ablation</time_frame>
    <description>MRI detected asymptomatic cerebrovascular events (ACE) at 30 days follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Acute Procedure Related Complications</measure>
    <time_frame>Day 30</time_frame>
    <description>The secondary endpoints included procedure-related complications (composite of any vascular complication, pericardial complication, heart block, thromboembolic event excluding stroke or TIA) and in-hospital mortality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Tamponade</measure>
    <time_frame>Day 30</time_frame>
    <description>Cardiac tamponade is a medical emergency that takes place when abnormal amounts of fluid accumulate in the pericardial sac compressing the heart and leading to a decrease in cardiac output and shock.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Fatal Pulmonary Embolism</measure>
    <time_frame>Day 30</time_frame>
    <description>A pulmonary embolism is a blood clot in the lung that occurs when a clot in another part of the body (often the leg or arm) moves through the bloodstream and becomes lodged in the blood vessels of the lung. This restricts blood flow to the lungs, lowers oxygen levels in the lungs and increases blood pressure in the pulmonary arteries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Progressive Heart Failure and Electromechanical Dissociation (EMD)</measure>
    <time_frame>Day 30</time_frame>
    <description>Heart failure means that the heart isn't pumping as well as it should be.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Groin Hematoma</measure>
    <time_frame>Day 30</time_frame>
    <description>A hematoma is a collection of blood outside of a blood vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Retroperitoneal Bleed</measure>
    <time_frame>Day 30</time_frame>
    <description>Retroperitoneal bleeding occurs when blood enters into space immediately behind the posterior reflection of the abdominal peritoneum. The organs of this space include the esophagus, aorta, inferior vena cava, kidneys, ureters, adrenals, rectum, parts of the duodenum, parts of the pancreas, and parts of the colon.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Heart Block</measure>
    <time_frame>Day 30</time_frame>
    <description>Heart block is a type of heart rhythm disorder (arrhythmia). It is the slowing down or interruption of the electrical signal from the upper chambers of the heart (the atria) to the lower chambers (the ventricles). The electrical signal causes the heart muscle to contract and the heart to beat.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With In-hospital Mortality</measure>
    <time_frame>Day 30</time_frame>
    <description>Death occurring during the hospital stay.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">246</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <condition>Premature Ventricular Contraction</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>DOAC (Direct Oral Anticoagulant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be asked to take standard dose approved for stroke prophylaxis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be asked to take 81 milligrams by mouth once per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOAC</intervention_name>
    <description>DOAC is a blood thinning drug, also called direct oral anticoagulant. These group of drugs are approved by the U.S. Food and Drug Administration (FDA) for the treatment of stroke prophylaxis in atrial fibrillation and deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.</description>
    <arm_group_label>DOAC (Direct Oral Anticoagulant)</arm_group_label>
    <other_name>Direct Oral Anti Coagulants</other_name>
    <other_name>Rivaroxaban</other_name>
    <other_name>Apixiban</other_name>
    <other_name>Dabigatran</other_name>
    <other_name>Edoxaban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.</description>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing radiofrequency catheter ablation for scar VT which includes VT&#xD;
             secondary to ischemic cardiomyopathy and non-ischemic cardiomyopathy&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy&#xD;
             test within 24 hours prior to the start of study drug&#xD;
&#xD;
          -  Women must not be breastfeeding&#xD;
&#xD;
          -  WOCBP must agree to follow instructions for method(s) of contraception for the&#xD;
             duration of treatment with Apixaban plus 33 days post-treatment completion&#xD;
&#xD;
          -  Males who are sexually active with WOCBP must agree to follow instructions for&#xD;
             method(s) of contraception for the duration of treatment and for a total of 93 days&#xD;
             post-treatment completion&#xD;
&#xD;
          -  Participants must agree to the use of one approved method of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of cerebral vascular accident/transient ischemic attack (CVA/TIA) in last 3&#xD;
             months&#xD;
&#xD;
          -  Cardiac surgery or neurosurgery within 3 months of the intended procedure date&#xD;
&#xD;
          -  Any active bleeding&#xD;
&#xD;
          -  Severe hypersensitivity reaction to ELIQUIS (including drug hypersensitivity, such as&#xD;
             skin rash and allergic reactions)&#xD;
&#xD;
          -  Participants cannot have prosthetic heart valves&#xD;
&#xD;
          -  History or bleeding and clotting disorders&#xD;
&#xD;
          -  Contraindications to Aspirin therapy&#xD;
&#xD;
          -  Contraindication to oral anticoagulation&#xD;
&#xD;
          -  Patient on an anticoagulant prior to the ablation for other primary indications like&#xD;
             atrial fibrillation (AF), deep vein thrombosis (DVT) or a mechanical valve&#xD;
&#xD;
          -  Evidence of intracardiac thrombus&#xD;
&#xD;
          -  Patient with Creatinine Clearance of &lt; 30 cc/min&#xD;
&#xD;
          -  Participation in another investigational study related to oral anticoagulation, drug&#xD;
             and/or device intervention&#xD;
&#xD;
          -  Claustrophobic patients&#xD;
&#xD;
          -  Implantable Cardioverter Defibrillator (ICD) generator placement before the year 2000&#xD;
&#xD;
          -  Has an ICD and is pacing dependent without underlying rhythm upon interrogation at&#xD;
             baseline&#xD;
&#xD;
          -  Patient has abandoned leads&#xD;
&#xD;
          -  Patients who are on p-glycoprotein inducers or inhibitors where the dose of Apixaban&#xD;
             cannot be effectively altered&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dhanunjaya Lakkireddy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kansas City Heart Rhythm Research Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KCHRF</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TCAI</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jayadeva Institute of Medical Sciences</name>
      <address>
        <city>Bengaluru</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cabral KP, Ansell JE. The role of factor Xa inhibitors in venous thromboembolism treatment. Vasc Health Risk Manag. 2015 Jan 30;11:117-23. doi: 10.2147/VHRM.S39726. eCollection 2015. Review.</citation>
    <PMID>25673997</PMID>
  </reference>
  <reference>
    <citation>Ghanbari H, Başer K, Jongnarangsin K, Chugh A, Nallamothu BK, Gillespie BW, Başer HD, Suwanagool A, Crawford T, Latchamsetty R, Good E, Pelosi F Jr, Bogun F, Morady F, Oral H. Mortality and cerebrovascular events after radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm. 2014 Sep;11(9):1503-11. doi: 10.1016/j.hrthm.2014.05.003. Epub 2014 May 6. Erratum in: Heart Rhythm. 2015 Jan;12(1):253. Swangasool, Arisara [corrected to Suwanagool, Arisara].</citation>
    <PMID>24813379</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 25, 2016</study_first_submitted>
  <study_first_submitted_qc>January 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2016</study_first_posted>
  <results_first_submitted>July 30, 2021</results_first_submitted>
  <results_first_submitted_qc>August 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 24, 2021</results_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiofrequency ablation</keyword>
  <keyword>anticoagulation</keyword>
  <keyword>Direct oral anticoagulants</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Ventricular arrhythmia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Ventricular Premature Complexes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
    <mesh_term>Coagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT02666742/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Men and women (with negative urine pregnancy test or non-breastfeeding) aged at least 18 years old were eligible for the study if they underwent radiofrequency ablation (RFA) for VT (secondary to ischemic or nonischemic cardiomyopathy) or PVC's.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Direct Oral Anticoagulant (DOAC)</title>
          <description>Participants will be asked to take a DOAC (Rivaroxaban/Apixiban/Dabigatran/Edoxaban) dose that is approved for stroke prophylaxis for 30 days post ablation&#xD;
DOAC: DOAC is a blood thinning drug, also called an anticoagulant. DOAC is approved by the U.S. Food and Drug Administration (FDA) for the prophylaxis of stroke in atrial fibrillation patients and treatment of deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.</description>
        </group>
        <group group_id="P2">
          <title>Aspirin</title>
          <description>Participants will be asked to take 81 milligrams by mouth once per day.&#xD;
Aspirin: Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
                <participants group_id="P2" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
                <participants group_id="P2" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients undergoing VT or PVC ablation are enrolled into the study. Baseline characteristics of patients including demographics, comorbidities, cardiac function etc were collected and analyzed</population>
      <group_list>
        <group group_id="B1">
          <title>DOAC</title>
          <description>Participants will be asked to take approved dose of the drug for stroke Px&#xD;
DOAC Apixaban is a blood thinning drug, also called an anticoagulant. DOAC is approved by the U.S. Food and Drug Administration (FDA) for stroke prophylaxis and the treatment of deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.</description>
        </group>
        <group group_id="B2">
          <title>Aspirin</title>
          <description>Participants will be asked to take 81 milligrams by mouth once per day.&#xD;
Aspirin: Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="123"/>
            <count group_id="B2" value="123"/>
            <count group_id="B3" value="246"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="123"/>
                    <count group_id="B2" value="123"/>
                    <count group_id="B3" value="246"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.6" spread="12.5"/>
                    <measurement group_id="B2" value="58.3" spread="14.7"/>
                    <measurement group_id="B3" value="59.95" spread="13.7438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="123"/>
                    <count group_id="B2" value="123"/>
                    <count group_id="B3" value="246"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anti-arrhythmic drugs</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="123"/>
                    <count group_id="B2" value="123"/>
                    <count group_id="B3" value="246"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Transient Ischemic Attack</title>
        <description>Transient ischemic attack(TIA) - defined as a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction.</description>
        <time_frame>First 30 days of post ablation</time_frame>
        <population>this is a population group undergoing VT or premature ventricular contraction (PVC) ablation</population>
        <group_list>
          <group group_id="O1">
            <title>DOAC</title>
            <description>DOAC is a blood thinner group</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>Participants will be asked to take 81 milligrams by mouth once per day.&#xD;
Aspirin: Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Transient Ischemic Attack</title>
          <description>Transient ischemic attack(TIA) - defined as a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction.</description>
          <population>this is a population group undergoing VT or premature ventricular contraction (PVC) ablation</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Due to lack of precedent robust clinical data, we performed exploratory study to evaluate safety and efficacy of DOAC vs. Aspirin (ASA) in patients undergoing left ventricular arrhythmia (LVA) ablation; therefore, sample size calculation was not undertaken.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Continuous variables were compared by two-sample t-tests and categorical variables by chi-square test. All tests were two-tailed, and a P value less than 0.05 was considered to indicate statistical significance. Bonferroni correction was not performed due to prespecified outcomes in the trial. Analyses were performed using GraphPad 6</non_inferiority_desc>
            <p_value>0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Stroke</title>
        <description>Stroke - incidence of ischemic stroke - defined as an episode of neurological dysfunction caused by focal cerebral, spinal, or retinal infarction.</description>
        <time_frame>First 30 days of post ablation</time_frame>
        <population>This is a population group undergoing VT or PVC ablation</population>
        <group_list>
          <group group_id="O1">
            <title>DOAC</title>
            <description>DOAC is a blood thinner group</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>Participants will be asked to take 81 milligrams by mouth once per day.&#xD;
Aspirin: Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stroke</title>
          <description>Stroke - incidence of ischemic stroke - defined as an episode of neurological dysfunction caused by focal cerebral, spinal, or retinal infarction.</description>
          <population>This is a population group undergoing VT or PVC ablation</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Asymptomatic Cerebral Event on MRI - 24 Hours</title>
        <description>MRI detected asymptomatic cerebrovascular events (ACE) at 24 hours.</description>
        <time_frame>24 Hours post ablation</time_frame>
        <population>This is a population group undergoing VT or PVC ablation</population>
        <group_list>
          <group group_id="O1">
            <title>DOAC</title>
            <description>Participants will be asked to take standard dose approved for stroke prophylaxis&#xD;
DOAC: DOAC is a blood thinning drug, also called direct oral anticoagulant. These group of drugs are approved by the U.S. Food and Drug Administration (FDA) for the treatment of stroke prophylaxis in atrial fibrillation and deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>Participants will be asked to take 81 milligrams by mouth once per day.&#xD;
Aspirin: Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Asymptomatic Cerebral Event on MRI - 24 Hours</title>
          <description>MRI detected asymptomatic cerebrovascular events (ACE) at 24 hours.</description>
          <population>This is a population group undergoing VT or PVC ablation</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Asymptomatic Cerebral Event on MRI - 30 Days</title>
        <description>MRI detected asymptomatic cerebrovascular events (ACE) at 30 days follow-up.</description>
        <time_frame>24 Hours to 30 days of post ablation</time_frame>
        <population>This is a population group undergoing VT or PVC ablation</population>
        <group_list>
          <group group_id="O1">
            <title>DOAC</title>
            <description>Participants will be asked to take standard dose approved for stroke prophylaxis&#xD;
DOAC: DOAC is a blood thinning drug, also called direct oral anticoagulant. These group of drugs are approved by the U.S. Food and Drug Administration (FDA) for the treatment of stroke prophylaxis in atrial fibrillation and deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>Participants will be asked to take 81 milligrams by mouth once per day.&#xD;
Aspirin: Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Asymptomatic Cerebral Event on MRI - 30 Days</title>
          <description>MRI detected asymptomatic cerebrovascular events (ACE) at 30 days follow-up.</description>
          <population>This is a population group undergoing VT or PVC ablation</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Acute Procedure Related Complications</title>
        <description>The secondary endpoints included procedure-related complications (composite of any vascular complication, pericardial complication, heart block, thromboembolic event excluding stroke or TIA) and in-hospital mortality.</description>
        <time_frame>Day 30</time_frame>
        <population>patients who meet inclusion criteria</population>
        <group_list>
          <group group_id="O1">
            <title>DOAC</title>
            <description>Participants will be asked to take DOAC as prescribed&#xD;
DOAC is a blood thinning drug, also called an anticoagulant. DOACs are approved by the U.S. Food and Drug Administration (FDA) for stroke prophylaxis and the treatment of deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>Participants will be asked to take 81 milligrams by mouth once per day.&#xD;
Aspirin: Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Procedure Related Complications</title>
          <description>The secondary endpoints included procedure-related complications (composite of any vascular complication, pericardial complication, heart block, thromboembolic event excluding stroke or TIA) and in-hospital mortality.</description>
          <population>patients who meet inclusion criteria</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Tamponade</title>
        <description>Cardiac tamponade is a medical emergency that takes place when abnormal amounts of fluid accumulate in the pericardial sac compressing the heart and leading to a decrease in cardiac output and shock.</description>
        <time_frame>Day 30</time_frame>
        <population>Patients who meet inclusion criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>DOAC</title>
            <description>Participants will be asked to take DOAC as prescribed&#xD;
DOAC is a blood thinning drug, also called an anticoagulant. DOACs are approved by the U.S. Food and Drug Administration (FDA) for stroke prophylaxis and the treatment of deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>Participants will be asked to take 81 milligrams by mouth once per day.&#xD;
Aspirin: Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Tamponade</title>
          <description>Cardiac tamponade is a medical emergency that takes place when abnormal amounts of fluid accumulate in the pericardial sac compressing the heart and leading to a decrease in cardiac output and shock.</description>
          <population>Patients who meet inclusion criteria.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Fatal Pulmonary Embolism</title>
        <description>A pulmonary embolism is a blood clot in the lung that occurs when a clot in another part of the body (often the leg or arm) moves through the bloodstream and becomes lodged in the blood vessels of the lung. This restricts blood flow to the lungs, lowers oxygen levels in the lungs and increases blood pressure in the pulmonary arteries.</description>
        <time_frame>Day 30</time_frame>
        <population>Patients who meet inclusion criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>DOAC</title>
            <description>Participants will be asked to take DOAC as prescribed&#xD;
DOAC is a blood thinning drug, also called an anticoagulant. DOACs are approved by the U.S. Food and Drug Administration (FDA) for stroke prophylaxis and the treatment of deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>Participants will be asked to take 81 milligrams by mouth once per day.&#xD;
Aspirin: Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Fatal Pulmonary Embolism</title>
          <description>A pulmonary embolism is a blood clot in the lung that occurs when a clot in another part of the body (often the leg or arm) moves through the bloodstream and becomes lodged in the blood vessels of the lung. This restricts blood flow to the lungs, lowers oxygen levels in the lungs and increases blood pressure in the pulmonary arteries.</description>
          <population>Patients who meet inclusion criteria.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Progressive Heart Failure and Electromechanical Dissociation (EMD)</title>
        <description>Heart failure means that the heart isn't pumping as well as it should be.</description>
        <time_frame>Day 30</time_frame>
        <population>Patients who meet inclusion criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>DOAC</title>
            <description>Participants will be asked to take DOAC as prescribed&#xD;
DOAC is a blood thinning drug, also called an anticoagulant. DOACs are approved by the U.S. Food and Drug Administration (FDA) for stroke prophylaxis and the treatment of deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>Participants will be asked to take 81 milligrams by mouth once per day.&#xD;
Aspirin: Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Progressive Heart Failure and Electromechanical Dissociation (EMD)</title>
          <description>Heart failure means that the heart isn't pumping as well as it should be.</description>
          <population>Patients who meet inclusion criteria.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Groin Hematoma</title>
        <description>A hematoma is a collection of blood outside of a blood vessel.</description>
        <time_frame>Day 30</time_frame>
        <population>Patients who meet inclusion criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>DOAC</title>
            <description>Participants will be asked to take DOAC as prescribed&#xD;
DOAC is a blood thinning drug, also called an anticoagulant. DOACs are approved by the U.S. Food and Drug Administration (FDA) for stroke prophylaxis and the treatment of deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>Participants will be asked to take 81 milligrams by mouth once per day.&#xD;
Aspirin: Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Groin Hematoma</title>
          <description>A hematoma is a collection of blood outside of a blood vessel.</description>
          <population>Patients who meet inclusion criteria.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Retroperitoneal Bleed</title>
        <description>Retroperitoneal bleeding occurs when blood enters into space immediately behind the posterior reflection of the abdominal peritoneum. The organs of this space include the esophagus, aorta, inferior vena cava, kidneys, ureters, adrenals, rectum, parts of the duodenum, parts of the pancreas, and parts of the colon.</description>
        <time_frame>Day 30</time_frame>
        <population>Patients who meet inclusion criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>DOAC</title>
            <description>Participants will be asked to take DOAC as prescribed&#xD;
DOAC is a blood thinning drug, also called an anticoagulant. DOACs are approved by the U.S. Food and Drug Administration (FDA) for stroke prophylaxis and the treatment of deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>Participants will be asked to take 81 milligrams by mouth once per day.&#xD;
Aspirin: Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Retroperitoneal Bleed</title>
          <description>Retroperitoneal bleeding occurs when blood enters into space immediately behind the posterior reflection of the abdominal peritoneum. The organs of this space include the esophagus, aorta, inferior vena cava, kidneys, ureters, adrenals, rectum, parts of the duodenum, parts of the pancreas, and parts of the colon.</description>
          <population>Patients who meet inclusion criteria.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Heart Block</title>
        <description>Heart block is a type of heart rhythm disorder (arrhythmia). It is the slowing down or interruption of the electrical signal from the upper chambers of the heart (the atria) to the lower chambers (the ventricles). The electrical signal causes the heart muscle to contract and the heart to beat.</description>
        <time_frame>Day 30</time_frame>
        <population>Patients who meet inclusion criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>DOAC</title>
            <description>Participants will be asked to take DOAC as prescribed&#xD;
DOAC is a blood thinning drug, also called an anticoagulant. DOACs are approved by the U.S. Food and Drug Administration (FDA) for stroke prophylaxis and the treatment of deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>Participants will be asked to take 81 milligrams by mouth once per day.&#xD;
Aspirin: Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Heart Block</title>
          <description>Heart block is a type of heart rhythm disorder (arrhythmia). It is the slowing down or interruption of the electrical signal from the upper chambers of the heart (the atria) to the lower chambers (the ventricles). The electrical signal causes the heart muscle to contract and the heart to beat.</description>
          <population>Patients who meet inclusion criteria.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With In-hospital Mortality</title>
        <description>Death occurring during the hospital stay.</description>
        <time_frame>Day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DOAC</title>
            <description>Participants will be asked to take DOAC as prescribed&#xD;
DOAC is a blood thinning drug, also called an anticoagulant. DOACs are approved by the U.S. Food and Drug Administration (FDA) for stroke prophylaxis and the treatment of deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>Participants will be asked to take 81 milligrams by mouth once per day.&#xD;
Aspirin: Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With In-hospital Mortality</title>
          <description>Death occurring during the hospital stay.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First 30 days of post ablation</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Apixaban</title>
          <description>Participants will be asked to take 5 milligrams by mouth twice per day.&#xD;
Apixaban: Apixaban is a blood thinning drug, also called an anticoagulant. Apixaban is approved by the U.S. Food and Drug Administration (FDA) for the treatment of deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.</description>
        </group>
        <group group_id="E2">
          <title>Aspirin</title>
          <description>Participants will be asked to take 81 milligrams by mouth once per day.&#xD;
Aspirin: Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Our results should be considered in light of several significant limitations. An important limitation was the lack of long-term follow-up and quality-of-life and neurocognitive function information. Another methodological limitation of the outcomes was that the ASA group did not get a loading dose, perhaps the delay in achieving the therapeutic effects in denovo ASA initiation could increase the risk of events.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Donita Atkins</name_or_title>
      <organization>Kansas City Heart Rhythm Institute</organization>
      <phone>913-253-3064</phone>
      <email>Donita.Atkins@hcahealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

